These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 19281081)
1. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. Hooper C; Calvert J Int J Chron Obstruct Pulmon Dis; 2008; 3(4):659-69. PubMed ID: 19281081 [TBL] [Abstract][Full Text] [Related]
2. Effect of CArbocisteine in Prevention of exaceRbation of chronic obstructive pulmonary disease (CAPRI study): An observational study. Esposito A; Valentino MR; Bruzzese D; Bocchino M; Ponticiello A; Stanziola A; Sanduzzi A Pulm Pharmacol Ther; 2016 Apr; 37():85-8. PubMed ID: 26970503 [TBL] [Abstract][Full Text] [Related]
3. Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis. Zeng Z; Yang D; Huang X; Xiao Z Int J Chron Obstruct Pulmon Dis; 2017; 12():2277-2283. PubMed ID: 28814855 [TBL] [Abstract][Full Text] [Related]
4. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Zheng JP; Kang J; Huang SG; Chen P; Yao WZ; Yang L; Bai CX; Wang CZ; Wang C; Chen BY; Shi Y; Liu CT; Chen P; Li Q; Wang ZS; Huang YJ; Luo ZY; Chen FP; Yuan JZ; Yuan BT; Qian HP; Zhi RC; Zhong NS Lancet; 2008 Jun; 371(9629):2013-8. PubMed ID: 18555912 [TBL] [Abstract][Full Text] [Related]
6. Use of mucolytics in COPD: A Delphi consensus study. Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537 [TBL] [Abstract][Full Text] [Related]
7. Carbocisteine for acute exacerbations of COPD. Waller P; Suissa S Lancet; 2008 Nov; 372(9650):1630; author reply 1631-2. PubMed ID: 18994655 [No Abstract] [Full Text] [Related]
8. Carbocisteine for acute exacerbations of COPD. Mohapatra PR; Aggarwal D Lancet; 2008 Nov; 372(9650):1630-1; author reply 1631-2. PubMed ID: 18994656 [No Abstract] [Full Text] [Related]
9. The effect and mechanism of action of carbocysteine on airway bacterial load in rats chronically exposed to cigarette smoke. Sun L; Tang L; Xu Y; Wang S; Li Y; Kang J Respirology; 2010 Oct; 15(7):1064-71. PubMed ID: 20807377 [TBL] [Abstract][Full Text] [Related]
10. Carbocisteine can scavenge reactive oxygen species in vitro. Nogawa H; Ishibashi Y; Ogawa A; Masuda K; Tsubuki T; Kameda T; Matsuzawa S Respirology; 2009 Jan; 14(1):53-9. PubMed ID: 19144049 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026 [TBL] [Abstract][Full Text] [Related]
12. A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial. Bradley JM; Anand R; O'Neill B; Ferguson K; Clarke M; Carroll M; Chalmers J; De Soyza A; Duckers J; Hill AT; Loebinger MR; Copeland F; Gardner E; Campbell C; Agus A; McGuire A; Boyle R; McKinney F; Dickson N; McAuley DF; Elborn S; Trials; 2019 Dec; 20(1):747. PubMed ID: 31856887 [TBL] [Abstract][Full Text] [Related]
13. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Macciò A; Madeddu C; Panzone F; Mantovani G Expert Opin Pharmacother; 2009 Mar; 10(4):693-703. PubMed ID: 19239402 [TBL] [Abstract][Full Text] [Related]
14. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease. Tatsumi K; Fukuchi Y; J Am Geriatr Soc; 2007 Nov; 55(11):1884-6. PubMed ID: 17979906 [No Abstract] [Full Text] [Related]
15. Efficacy of carbocisteine in the treatment of chronic obstructive pulmonary disease and impact on the quality of life. Alibašić E; Skopljak A; Čengić A; Krstović G; Trifunović N; Čatić T; Kapo B; Mehić M; Hadžimuratović A Med Glas (Zenica); 2017 Aug; 14(2):182-188. PubMed ID: 28786969 [TBL] [Abstract][Full Text] [Related]
16. A mucoactive drug carbocisteine ameliorates steroid resistance in rat COPD model. Song Y; Yu P; Lu JJ; Lu HZ; Zhu L; Yu ZH; Chen HZ; Cui YY Pulm Pharmacol Ther; 2016 Aug; 39():38-47. PubMed ID: 27328977 [TBL] [Abstract][Full Text] [Related]
18. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Carpagnano GE; Resta O; Foschino-Barbaro MP; Spanevello A; Stefano A; Di Gioia G; Serviddio G; Gramiccioni E Eur J Pharmacol; 2004 Nov; 505(1-3):169-75. PubMed ID: 15556150 [TBL] [Abstract][Full Text] [Related]
19. A prospective study of the effects of carbocysteine lysine salt on frequency of exacerbations in COPD patients treated with or without inhaled steroids. Paone G; Lanata L; Saibene F; Toti S; Palermo P; Graziani C; Flore MC; Ramaccia M; Puglisi G Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6727-6735. PubMed ID: 31378916 [TBL] [Abstract][Full Text] [Related]